[1] Moroldo M, Munyaka PM, Lecardonnel J,et al. Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLA minipigs. Sci Rep,2020,10(1):234. [2] Wang S, Cai B, Han X,et al. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: a protocol for a systematic review and meta-analysis. Medicine (Baltimore), 2020,99(19):e20148. [3] Leylabadlo HE, Kafil HS, Farajnia S,et al. Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus. Eur J Gastroenterol Hepatol,2021,33(1):548-554. [4] Zhou Q, Wang Y, Wang J, et al. Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine (Baltimore), 2021,100(10):e24940. [5] Kalantarhormozi M, Jouyan N, Asadipooya K,et al. Evaluation of adipokines, adiponectin, visfatin, andomenntin in uncomplicated type I diabetes patients before and after treatment of diabetic ketoacidosis. J Endocrinol Invest, 2020,43(12):1723-1727. [6] Buckner T, Shao B, Eckel RH, et al. Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes. J Clin Lipidol,2021,15(1):235-242. [7] Nordklint AK, Almdal TP, Vestergaard P,et al. Effect ofmetformin vs. Placebo in combination with insulin analogues on bone markers P1NP and CTX in patients with type 2 diabetes mellitus. Calcif Tissue Int, 2020,107(2):160-169. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):23-29. [9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南( 2017年版) .中华糖尿病杂志,2018,10(1) :4- 67. [10] 中国肝病学会脂肪肝与酒精性肝病研究组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3):161-163. [11] Cigrovski-Berkovic M, Virovic-Jukic L, Bilic-Curcic I,et al. Post-transplant diabetes mellitus and preexisting liver disease-a bidirectional relationship affecting treatment and management. World J Gastroenterol, 2020,26(21):2740-2757. [12] Biscetti F, Nardella E, Rando MM,et al. Association betweenomentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc Diabetol, 2020,19(1):170. [13] Montazerifar F, Bakhshipour AR, Karajibani M,et al. Serumomentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci,2017,30(22):70. [14] Bekaert M, Ouwens DM, Horbelt T,et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity,2016,24(12):2544-2552. [15] Izadi A, Aliasghari F, Gargari BP,et al. Strong association between serum vitamin D and vaspin levels, AIP, VAI and liver enzymes in NAFLD patients. Int J Vitam Nutr Res, 2020,90(1):59-66. [16] Scotece M, Koskinen-Kolasa A, Pemmari A, et al. Novel adipokine associated with OA: retinol binding protein 4 (RBP4) is produced by cartilage and is correlated with MMPs in osteoarthritis patients. Inflamm Res,2020 69(4):415-421. [17] Tsai YL, Liu CW, Huang SF,et al. Urinary fatty acid and retinol binding protein-4 predict CKD progression in severe NAFLD patients with hypertension: 4-year study with clinical and experimental approaches. Medicine,2020 99(2):e18626. [18] T0njes A, Blüher M, Stumvoll M. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease. Curr Pharm Des, 2010, 16(17):1921-1928. [19] Lebedev DA, Lyasnikova EA, Vasilyeva EY,et al. Type 2 diabetes mellitus and chronic heart failure with midrange and preserved ejection fraction: a focus on serum biomarkers of fibrosis. J Diabetes Res, 2020,69(7):76153. [20] Fan S, Wang Z, Li Q,et al. The relationship between BSP mRNA expression and 25(OH)D/OPG in peripheral blood of newly diagnosed T2DM patients with different bone mass. Endokrynol Pol, 2020,71(2):160-167. |